cncpt-artikel_lb_atf
ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses
This article is about the findings of the CONTACT-02 study, highlighting the efficacy of cabozantinib and atezolizumab in treating metastatic castration-resistant prostate cancer (mCRPC) presented at ASCO GU 2024.